Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2990 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Josephine Harrington und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Duke University Department of Medicine, Durham, NC, USA. Hauptthemen laut MEDLINE: Heart Failure, Diabetes Mellitus, Type 2, Myocardial Infarction. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim and Eli Lilly.
Abstract (Originalsprache)
Aims
Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in post-acute myocardial infarction (AMI) patients is unknown. Methods and results The Study to Test the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction (EMPACT-MI) trial screened 6610 participants with AMI and randomized 6522 to empagliflozin or placebo in addition to standard of care. The median (interquartile) age was 64 (56–71) years and 75.1% of patients were male. Major comorbidities included hypertension (69.1%), type 2 diabetes (31.7%), prior myocardial infarction (13.0%), and atrial fibrillation (10.9%). The majority (74.3%) of patients presented with an ST-elevation myocardial infarction. Overall, 56.9% of patients had acute signs or symptoms of congestion requiring treatment and 78.3% had left ventricular systolic dysfunction with ejection fraction <45%. Clinical characteristics, including baseline demographics, rates of revascularization, and cardiovascular medications at discharge were largely comparable to recent trials of the post-AMI population.
Conclusion
The EMPACT-MI trial will establish the benefit and risks of empagliflozin treatment in patients with AMI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Duke University Department of Medicine, Durham, NC, USA.
- Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.
- Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, all at University of Toronto, Toronto, ON, Canada.
- Department of Cardiology (CVK) of German Heart Center Charité; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedi…
- Institute of Heart Disease, Wroclaw Medical University, Wroclaw, Poland.
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, NY, USA.
Förderung
- Boehringer Ingelheim and Eli Lilly
Zitieren
APA
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Andersen, K. R., Sumin, M., Zwiener, I., Hernandez, A. F., & Butler, J. (2023). Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2990
Vancouver
Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, et al. Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2990
BibTeX
@article{Harrington2023,
author = {Harrington, Josephine and Udell, Jacob A and Jones, W Schuyler and Anker, Stefan D and Bhatt, Deepak L and Petrie, Mark C and Andersen, Knut Robert and Sumin, Mikhail and Zwiener, Isabella and Hernandez, Adrian F and Butler, Javed},
title = {Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2990}
}
EUVIMED